• About us
• Contact

Advertisement

Organisation › Details

bioMérieux S.A. (Euronext: BIM)

A world leader in the field of in vitro diagnostics for over 45 years, bioMérieux is present in more than 150 countries through 39 subsidiaries and a large network of distributors. In 2008, revenues reached €1.111 billion with 84% of sales outside of France. bioMérieux provides diagnostic solutions (reagents, instruments, software) which determine the source of disease and contamination to improve patient health and ensure consumer safety. Our products are used for diagnosing infectious diseases and providing high medical value results for cancer screening and monitoring and cardiovascular emergencies. They are also used for detecting microorganisms in agri-food, pharmaceutical and cosmetic products. bioMérieux is listed on the NYSE Euronext Paris market (Symbol: BIM - ISIN: FR0010096479). Other information can be found at www.biomerieux.com. *

 

	Start	1999-09-09 existent
	Group	Mérieux (Group)
	Industry	BIOTECH
	Person	Mérieux, Alexandre (Mérieux 201712– CEO at bioMérieux before Deputy CEO before VP Industrial Microbiology)
	Person 2	Bélingard, Jean-Luc (Mérieux 201101– Président Directeur Général before Ipsen CEO + Pierre Fabre + Roche Diagnostics)
	Region	Marcy-l’Étoile, Rhône
	Country	France
	City	69280 Marcy l’Étoile
	Tel	+33-4-7887-2000
		Address record changed: 2024-01-05
Basic data	Employees	H: 10,001 to 50,00 (2017-12-31)
	Currency	EUR
	Annual sales	2,288,200,000 (sales, net, consolidated (2017) 2017-12-31)
	Profit	237,600,000 (2017-12-31)
	Cash	312,100,000 (2017-12-31)
		* Document for »About Section«:
		Record changed: 2026-02-05

Advertisement

More documents for Mérieux (Group)

• [1] bioMérieux S.A.. (1/22/26). "Press Release: bioMérieux Acquires Accellix to Elevate Pharmaceutical Quality Control and Accelerate Advanced Therapies". Marcy l’Étoile....
• [2] bioMérieux S.A.. (6/16/25). "Press Release: bioMérieux Strengthens Its Next-generation Sequencing Capabilities with the Acquisition of Day Zero Diagnostics Solutions and Technologies". Marcy l’Étoile....
• [3] bioMérieux S.A.. (3/18/25). "Press Release: bioMérieux Receives FDA 510(k) Clearance for Its Vitek Compact Pro, a New ID/AST System to Fight against Antimicrobial Resistance". Marcy l’Étoile....
• [4] bioMérieux S.A.. (1/13/25). "Press Release: bioMérieux Strengthens Its Point of Care Presence with the Acquisition of the Immunoassay Start-up SpinChip". Marcy l’Étoile....
• [5] bioMérieux S.A.. (1/13/25). "Press Release: bioMérieux to Present at the 43rd Annual J.P. Morgan HealthCare Conference". Marcy l’Étoile....
• [6] bioMérieux S.A.. (1/13/25). "Press Release: SpinChip Diagnostics to be Acquired by bioMérieux". Oslo....
• [7] Mérieux NutriSciences Corporation. (10/7/24). "Press Release: Mérieux NutriSciences Enters Agreement to Acquire Worldwide Food Testing Business of Bureau Veritas". Chicago, IL....
• [8] bioMérieux S.A.. (10/19/23). "Press Release: bioMérieux Makes Strategic Investment in Oxford Nanopore". Oxford & Marcy-l’Etoile....
• [9] bioMérieux S.A.. (4/14/23). "Press Release: Oxford Nanopore and bioMérieux to Enter into a Strategic Partnership Agreement to Develop Innovative Infectious Disease Diagnostics". Oxford & Marcy-l’Etoile....
• [10] InDevR, Inc.. (1/17/23). "Press Release: InDevR Raises $9 Million in Series B Financing and Partners with bioMérieux". Boulder, CO....

To subscribe to our free, monthly mass spectrometry newsletter, please send an e-mail to info@iito.de and simply fill the subject line with the word »MSC Newsletter«

Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]

Please visit also our web portals for the Eurpean life sciences and the life sciences in German-speaking Europe (DE, AT & CH) at Life-Sciences-Germany.com and Life-Sciences-Europe.com

Advertisement

» top

» Imprint  |  » Data Privacy  |  » Contact  |  The use of this website requires to accept the » Disclaimer!   |  A project of [iito] Business Intelligence © 2002-2026. Made in Germany.